Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin
DRUG: SGN-40
Objective response as assessed by CT and PET scans and revised response criteria for malignant lymphoma., Every 1 or 2 months
Progression-free survival, disease-free survival, and overall survival., Study duration|Adverse events, laboratory values, and anti-drug antibody immune responses., Within 3 weeks of final infusion|PK profile., Within 3 weeks of final infusion
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.